ACAD ACADIA Pharmaceuticals Inc.

+0.06  (0.15%)
Previous Close 39.22
Open 39.03
Price To book 8.22
Market Cap 4.76B
Shares 121,113,000
Volume 1,674,691
Short Ratio 10.21
Av. Daily Volume 2,430,070

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiated November 2016.
Adjunctive treatment in patients with negative symptoms of schizophrenia
Phase 3 initiated November 2016.
Adjunctive treatment of schizophrenia
Phase 2 trial initiated October 2016.
Pimavanserin - SERENE
Alzheimer’s disease agitation
Approved April 29 2016
Parkinson’s disease psychosis (PDP)
Phase 2 top-line data released December 20, 2016. Primary endpoint met. Key secondary endpoint missed.
Alzheimer’s disease psychosis

Latest News

  1. ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2016 Financial Results on February 28, 2017
  2. Biotech Stock Mailbag: Bulls Love a Distracted Trump, Protalix, Acadia, Sarepta
  3. Acadia Pharmaceuticals Surge Higher Is More Than M&A Rumors
  4. Price Bump From M&A Rumors Earns Acadia A Vetr Downgrade
  5. Caution: Acadia Pharmaceuticals Is Overvalued
  6. A Potential $20 Billion Indication? 2 Must-Have Biotechs Taking on Alzheimer's Disease
  7. The Market In 5 Minutes: One For The Thumb
  8. Acadia Pops on Takeout Rumors, But Don't Buy on M&A Just Yet
  9. Forget GW Pharmaceuticals -- These 2 Stocks Are Better Buys
  10. Forget Anavex Life Sciences Corp.: These 2 Biotech Stocks Are Better Buys
  11. Biotech Acquisitions on the Rise in 2017: Latest Reports on Antares Pharma and ACADIA Pharmaceuticals
  12. How Risky Is Acadia Pharmaceuticals Stock?
  13. Why Acadia Pharmaceuticals Inc. Stock Slipped 19% in 2016
  14. Top Stocks to Buy in 2017
  15. 3 Companies Whose Sales Could Double in 2017
  16. Acadia Pharmaceuticals' Alzheimer's Data Raises Some Questions
  17. 3 ideas to improve waiting for your trades
  18. #1 issue top traders want to fix in 2017 on our prop desk
  19. The Market In 5 Minutes: Jobless Claims Fall Again, Retailers Struggle
  20. Why Encana, Acadia Pharmaceuticals, and Tenet Healthcare Jumped Today